Asset Prioritization

Develop R&D strategy with reliable analysis of your asset group and come up focused list of prioritized assets.
Request for proposal
Any company’s bundle of assets are of vital importance to them. What needs to be assessed is how important they can become in a clinical setting, and how much these assets might lead to a sizeable return on investment to the company.

Our Perspective

DelveInsight’s Asset Prioritization methodology employs intuitive assessments to initiate the client’s R&D journey. DelveInsight’s analysts work with the client team to develop intelligent criteria, create assessment scenarios through reliable parameters of importance and define situations for consequence of possible successes and failures. Our Asset Prioritization service provides understanding future market dynamics through market modelling, unmet medical needs for future understanding of treatment regimens, and thus, help create a sound strategy for company’s research and development.
Our Asset Prioritization methodology provides:

Insights

Assest prioritization study

Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio, and was interested to assess best possible asset for atrial fibrillation [...]

Market & Competitive Assessment study

Market & Competitive Assessment

A large Asian conglomerate was working to develop their asset portfolio in Cell Imaging and Analysis, and was interested to assess the market scenario of software based devices in... [...]

Portfolio Management study

Portfolio Management

A small-Pharma client based in Israel involved DelveInsight to manage their portfolio of candidates indicated for various infectious diseases. [...]

In-licensing opportunity study

In-Licensing Opportunity

A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe [...]

Request For Proposal

*I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.